This drug alone can add up to big bucks. The 3 mil will keep us in the black into next year and by then something else will happen, ie: Rexista partnership with BIG BUCKS up front. BEST IN CLASS.
Angelo, usually is very difficult to get the exact % of profit sharing.
I think that the fact they are going to manufacture the compound gives a much more interesting perspective on how much money IPCI is going to make from these generics: we have cost+plus for manufacture and probably a good profit sharing (your suggestion of 50/50 would be Amazing to me).
I think that if we get Focalin remaining strenghts in a short time IPCI is going to increase tremendously its negotiation power (due to cash in their hands) for Rexista-Podras.
Would love to some some buying crazyness at somepoint on this stock...but even a Tobira-like jump (8x overnight) would make me superhappy and willing to wait some more months.